114 related articles for article (PubMed ID: 21725605)
1. Temozolomide decreases invasion of glioma stem cells by down-regulating TGF-β2.
Zhang D; Jing Z; Qiu B; Wu A; Wang Y
Oncol Rep; 2011 Oct; 26(4):901-8. PubMed ID: 21725605
[TBL] [Abstract][Full Text] [Related]
2. A novel drug conjugate, NEO212, targeting proneural and mesenchymal subtypes of patient-derived glioma cancer stem cells.
Jhaveri N; Agasse F; Armstrong D; Peng L; Commins D; Wang W; Rosenstein-Sisson R; Vaikari VP; Santiago SV; Santos T; Chen L; Schönthal AH; Chen TC; Hofman FM
Cancer Lett; 2016 Feb; 371(2):240-50. PubMed ID: 26683773
[TBL] [Abstract][Full Text] [Related]
3. NEO212 Inhibits Migration and Invasion of Glioma Stem Cells.
Marín-Ramos NI; Thein TZ; Cho HY; Swenson SD; Wang W; Schönthal AH; Chen TC; Hofman FM
Mol Cancer Ther; 2018 Mar; 17(3):625-637. PubMed ID: 29440289
[TBL] [Abstract][Full Text] [Related]
4. Triacetin-based acetate supplementation as a chemotherapeutic adjuvant therapy in glioma.
Tsen AR; Long PM; Driscoll HE; Davies MT; Teasdale BA; Penar PL; Pendlebury WW; Spees JL; Lawler SE; Viapiano MS; Jaworski DM
Int J Cancer; 2014 Mar; 134(6):1300-10. PubMed ID: 23996800
[TBL] [Abstract][Full Text] [Related]
5. Enhanced MGMT expression contributes to temozolomide resistance in glioma stem-like cells.
Qiu ZK; Shen D; Chen YS; Yang QY; Guo CC; Feng BH; Chen ZP
Chin J Cancer; 2014 Feb; 33(2):115-22. PubMed ID: 23958055
[TBL] [Abstract][Full Text] [Related]
6. Neural stem/progenitors and glioma stem-like cells have differential sensitivity to chemotherapy.
Gong X; Schwartz PH; Linskey ME; Bota DA
Neurology; 2011 Mar; 76(13):1126-34. PubMed ID: 21346220
[TBL] [Abstract][Full Text] [Related]
7. New advances of microRNAs in glioma stem cells, with special emphasis on aberrant methylation of microRNAs.
Zhao B; Bian EB; Li J; Li J
J Cell Physiol; 2014 Sep; 229(9):1141-7. PubMed ID: 24374932
[TBL] [Abstract][Full Text] [Related]
8. Temozolomide increases MHC-I expression via NF-κB signaling in glioma stem cells.
Zhang D; Qiu B; Wang Y; Guan Y; Zhang L; Wu A
Cell Biol Int; 2017 Jun; 41(6):680-690. PubMed ID: 28403532
[TBL] [Abstract][Full Text] [Related]
9. Promoting oligodendroglial-oriented differentiation of glioma stem cell: a repurposing of quetiapine for the treatment of malignant glioma.
Wang Y; Huang N; Li H; Liu S; Chen X; Yu S; Wu N; Bian XW; Shen HY; Li C; Xiao L
Oncotarget; 2017 Jun; 8(23):37511-37524. PubMed ID: 28415586
[TBL] [Abstract][Full Text] [Related]
10. EMAP-II sensitize U87MG and glioma stem-like cells to temozolomide via induction of autophagy-mediated cell death and G2/M arrest.
Yu Q; Liu L; Wang P; Yao Y; Xue Y; Liu Y
Cell Cycle; 2017 Jun; 16(11):1085-1092. PubMed ID: 28436750
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of Sonic hedgehog and Notch pathways enhances sensitivity of CD133(+) glioma stem cells to temozolomide therapy.
Ulasov IV; Nandi S; Dey M; Sonabend AM; Lesniak MS
Mol Med; 2011; 17(1-2):103-12. PubMed ID: 20957337
[TBL] [Abstract][Full Text] [Related]
12. Down-Regulation of AQP4 Expression via p38 MAPK Signaling in Temozolomide-Induced Glioma Cells Growth Inhibition and Invasion Impairment.
Chen Y; Gao F; Jiang R; Liu H; Hou J; Yi Y; Kang L; Liu X; Li Y; Yang M
J Cell Biochem; 2017 Dec; 118(12):4905-4913. PubMed ID: 28569417
[TBL] [Abstract][Full Text] [Related]
13. miR-125b inhibitor may enhance the invasion-prevention activity of temozolomide in glioblastoma stem cells by targeting PIAS3.
Shi L; Wan Y; Sun G; Zhang S; Wang Z; Zeng Y
BioDrugs; 2014 Feb; 28(1):41-54. PubMed ID: 23857508
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of Onalespib, a Long-Acting Second-Generation HSP90 Inhibitor, as a Single Agent and in Combination with Temozolomide against Malignant Gliomas.
Canella A; Welker AM; Yoo JY; Xu J; Abas FS; Kesanakurti D; Nagarajan P; Beattie CE; Sulman EP; Liu J; Gumin J; Lang FF; Gurcan MN; Kaur B; Sampath D; Puduvalli VK
Clin Cancer Res; 2017 Oct; 23(20):6215-6226. PubMed ID: 28679777
[No Abstract] [Full Text] [Related]
15. Inhibition of TGF-beta2 with AP 12009 in recurrent malignant gliomas: from preclinical to phase I/II studies.
Hau P; Jachimczak P; Schlingensiepen R; Schulmeyer F; Jauch T; Steinbrecher A; Brawanski A; Proescholdt M; Schlaier J; Buchroithner J; Pichler J; Wurm G; Mehdorn M; Strege R; Schuierer G; Villarrubia V; Fellner F; Jansen O; Straube T; Nohria V; Goldbrunner M; Kunst M; Schmaus S; Stauder G; Bogdahn U; Schlingensiepen KH
Oligonucleotides; 2007; 17(2):201-12. PubMed ID: 17638524
[TBL] [Abstract][Full Text] [Related]
16. Gene expression profiles predicting the response to IFN-β and a combination of temozolomide and IFN-β in malignant gliomas.
Yoshino A; Tashiro S; Ogino A; Yachi K; Ohta T; Fukushima T; Watanabe T; Katayama Y; Okamoto Y; Sano E; Tsumoto K
Int J Oncol; 2011 Sep; 39(3):529-42. PubMed ID: 21805051
[TBL] [Abstract][Full Text] [Related]
17. Bone morphogenetic protein 4 inhibits cell proliferation and induces apoptosis in glioma stem cells.
Zhou Z; Sun L; Wang Y; Wu Z; Geng J; Miu W; Pu Y; You Y; Yang Z; Liu N
Cancer Biother Radiopharm; 2011 Feb; 26(1):77-83. PubMed ID: 21355779
[TBL] [Abstract][Full Text] [Related]
18. TMZ-induced PrPc/par-4 interaction promotes the survival of human glioma cells.
Zhuang D; Liu Y; Mao Y; Gao L; Zhang H; Luan S; Huang F; Li Q
Int J Cancer; 2012 Jan; 130(2):309-18. PubMed ID: 21328340
[TBL] [Abstract][Full Text] [Related]
19. Methylation mediated silencing of miR-23b expression and its role in glioma stem cells.
Geng J; Luo H; Pu Y; Zhou Z; Wu X; Xu W; Yang Z
Neurosci Lett; 2012 Oct; 528(2):185-9. PubMed ID: 22982144
[TBL] [Abstract][Full Text] [Related]
20. IL-10 and TGF-β2 are overexpressed in tumor spheres cultured from human gliomas.
Qiu B; Zhang D; Wang C; Tao J; Tie X; Qiao Y; Xu K; Wang Y; Wu A
Mol Biol Rep; 2011 Jun; 38(5):3585-91. PubMed ID: 21088899
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
